Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
FEASIBILITY OF TUMOR IMAGING USING L-3-[IODINE-123]-IODO-ALPHA-METHYL-TYROSINE IN EXTRACRANIAL TUMORS
Autore:
JAGER PL; FRANSSEN EJF; KOOL W; SZABO BG; HOEKSTRA HJ; GROEN HJM; DEVRIES EGE; VANIMHOFF GW; VAALBURG W; PIERS DA;
Indirizzi:
UNIV GRONINGEN HOSP,DEPT NUCL MED,POB 30001 NL-9700 RB GRONINGEN NETHERLANDS UNIV GRONINGEN HOSP,DEPT RADIOTHERAPY NL-9700 RB GRONINGEN NETHERLANDS UNIV GRONINGEN HOSP,DEPT SURG ONCOL NL-9700 RB GRONINGEN NETHERLANDS UNIV GRONINGEN HOSP,DEPT PULMONOL NL-9700 RB GRONINGEN NETHERLANDS UNIV GRONINGEN HOSP,DEPT MED ONCOL NL-9700 RB GRONINGEN NETHERLANDS UNIV GRONINGEN HOSP,DEPT HEMATOL NL-9700 RB GRONINGEN NETHERLANDS UNIV GRONINGEN HOSP,PET CTR NL-9700 RB GRONINGEN NETHERLANDS
Titolo Testata:
The Journal of nuclear medicine
fascicolo: 10, volume: 39, anno: 1998,
pagine: 1736 - 1743
SICI:
0161-5505(1998)39:10<1736:FOTIUL>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALPHA-METHYL TYROSINE; BRAIN-TUMORS; AMINO-ACIDS; L-3-)I-123>IODO-ALPHA-METHYL TYROSINE; PET; SPECT; ACCUMULATION; TISSUE; INVIVO; CELLS;
Keywords:
TUMOR IMAGING; AMINO ACIDS; I-123 METHYL-TYROSINE; SPECT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
P.L. Jager et al., "FEASIBILITY OF TUMOR IMAGING USING L-3-[IODINE-123]-IODO-ALPHA-METHYL-TYROSINE IN EXTRACRANIAL TUMORS", The Journal of nuclear medicine, 39(10), 1998, pp. 1736-1743

Abstract

L-3-[I-123]-lodo-alpha-methyl-tyrosine (IMT) is a modified amino acid. It is reported to be avidly taken up in brain tumors, reflecting amino acid transport and is suitable for SPECT. Methods: To determine whether tumors outside the brain can also accumulate this tracer, we injected 300-450 MBq IMT into 20 patients with different tumors [5 breast cancers, 4 lung tumors (1 benign), 2 carcinoid liver metastases, 4 soft-tissue tumors (1 benign), 3 malignant lymphomas and 2 primary brain tumors]. Tumor size ranged from 1-12 cm. Imaging was repeated after radiotherapy in two patients with breast cancer. Histology was availablein all cases. Dynamic scans, whole-body imaging and SPECT were performed during the first hour and 3 hr after injection. Plasma samples were analyzed for IMT, free I-123 and other metabolites. Results: All primary tumors were visualized. Tumor-to-background ratios ranged from 1.1 to 3.8 on planar and from 1.3 to 6.2 on SPECT images. Tumor uptake peaked in the first hour. Two carcinoid lesions in the liver tumors exhibited no IMT uptake above liver background. Tumor-to-background ratios in a benign bone inflammatory process and a focal pulmonary vasculitis were less than 1,2 (planar) and 1.9 (SPECT) and could be differentiated from uptake in all malignant nonbrain tumors. IMT was rapidly cleared from the plasma [3.6% +/- 0.6% (mean +/- s.d.) injected dose/liter at 10 min postinjection]. Minor in vivo deiodination was present (<1% of injected dose 1 hr postinjection). No other metabolites were found. Normal distribution consists of some uptake in the brain, liver, spleen, muscles, pancreatic region and intestinal structures and massiveuptake and excretion in the kidneys and bladder. Conclusion: IMT has potential as a metabolic tracer in tumors outside the brain.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/01/21 alle ore 06:37:13